Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New DNA test could speed up pneumonia diagnosis in ICU patients

NCT ID NCT05979350

Diagnosis Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new DNA-sequencing technique (metagenomic next-generation sequencing) can identify the cause of pneumonia faster than standard methods. About 114 ICU patients on ventilators will be randomly assigned to receive either the new test or usual care. The goal is to see if faster diagnosis leads to better antibiotic use, shorter hospital stays, and lower death rates.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metagenomic next-generation sequencing (mNGS) test
What this could lead to
If successful, this could make pneumonia diagnosis faster and more accurate, helping doctors choose the right antibiotics sooner and potentially reducing hospital stays and deaths.
What could go wrong
This is a relatively small trial (114 participants) and focuses on diagnostic accuracy, not a new treatment. The test may not improve patient outcomes significantly, and its benefits may not apply to all pneumonia patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

114 people

The number who actually took part.

Started

Aug 2023

Expected to finish

Nov 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Presenting to the ICU with a diagnosis of pneumonia (fulfilled with both radiographic and clinical criteria) 2. Adults aged ≥18 years 3. Orotracheally intubated 4. ICU admission for \<24 hours 5. APACHE II score \<35 on ICU admission Exclusion Criteria: 1. Life expectancy below 4 weeks 2. With an existing directive to withhold life-sustaining treatment 3. Patients not willing or able to provide a lower respiratory tract sample at ICU admission 4. Previous work-up has identified specific pathogens which can account for the index event of pneumonia 5. Multiplex PCR or NGS testing has been done for pathogen detection before screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diagnosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease pneumonia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diagnosis Pneumonia

Contacts and locations

Locations

  • National Taiwan University Hospital

    Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.